6/5
06:55 am
life
Timothy Coughlin Bought 833% More Shares In aTyr Pharma [Yahoo! Finance]
Neutral
Report
Timothy Coughlin Bought 833% More Shares In aTyr Pharma [Yahoo! Finance]
6/3
08:08 am
life
aTyr Pharma Announces Nasdaq Stock Ticker Symbol Change from “LIFE” to “ATYR” [Yahoo! Finance]
Medium
Report
aTyr Pharma Announces Nasdaq Stock Ticker Symbol Change from “LIFE” to “ATYR” [Yahoo! Finance]
6/3
08:00 am
life
aTyr Pharma Announces Nasdaq Stock Ticker Symbol Change from “LIFE” to “ATYR”
Medium
Report
aTyr Pharma Announces Nasdaq Stock Ticker Symbol Change from “LIFE” to “ATYR”
5/24
04:05 pm
life
aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) [Yahoo! Finance]
Neutral
Report
aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) [Yahoo! Finance]
5/24
04:00 pm
life
aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
5/15
07:00 am
life
aTyr Pharma to Present Poster Describing Efzofitimod’s Mechanism of Action at the American Thoracic Society 2024 International Conference
Medium
Report
aTyr Pharma to Present Poster Describing Efzofitimod’s Mechanism of Action at the American Thoracic Society 2024 International Conference
5/14
11:45 am
life
aTyr Pharma, Inc. (NASDAQ: LIFE) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $35.00 price target on the stock.
Medium
Report
aTyr Pharma, Inc. (NASDAQ: LIFE) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $35.00 price target on the stock.
5/14
08:15 am
life
aTyr Pharma Announces Second Positive DSMB Review for Efzofitimod in Phase 3 EFZO-FIT™ Study in Pulmonary Sarcoidosis [Yahoo! Finance]
Medium
Report
aTyr Pharma Announces Second Positive DSMB Review for Efzofitimod in Phase 3 EFZO-FIT™ Study in Pulmonary Sarcoidosis [Yahoo! Finance]
5/14
08:00 am
life
aTyr Pharma Announces Second Positive DSMB Review for Efzofitimod in Phase 3 EFZO-FIT™ Study in Pulmonary Sarcoidosis
Neutral
Report
aTyr Pharma Announces Second Positive DSMB Review for Efzofitimod in Phase 3 EFZO-FIT™ Study in Pulmonary Sarcoidosis
5/6
08:00 am
life
aTyr Pharma to Present at Upcoming Investor Conferences
Medium
Report
aTyr Pharma to Present at Upcoming Investor Conferences
5/3
05:07 pm
life
aTyr Pharma, Inc. (NASDAQ: LIFE) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $35.00 price target on the stock.
Low
Report
aTyr Pharma, Inc. (NASDAQ: LIFE) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $35.00 price target on the stock.
5/2
04:13 pm
life
aTyr Pharma Announces First Quarter 2024 Results and Provides Corporate Update [Yahoo! Finance]
Low
Report
aTyr Pharma Announces First Quarter 2024 Results and Provides Corporate Update [Yahoo! Finance]
5/2
04:00 pm
life
aTyr Pharma Announces First Quarter 2024 Results and Provides Corporate Update
Low
Report
aTyr Pharma Announces First Quarter 2024 Results and Provides Corporate Update
4/21
11:00 am
life
aTyr Pharma Insiders Placed Bullish Bets Worth US$514.6k [Yahoo! Finance]
Low
Report
aTyr Pharma Insiders Placed Bullish Bets Worth US$514.6k [Yahoo! Finance]
4/1
08:00 am
life
aTyr Pharma to Participate in April Investor Conferences
Medium
Report
aTyr Pharma to Participate in April Investor Conferences